Combined oral contraceptives and venous thromboembolism: review and perspective to mitigate the risk

L Morimont, H Haguet, JM Dogné, U Gaspard… - Frontiers in …, 2021 - frontiersin.org
Many factors must be considered and discussed with women when initiating a contraceptive
method and the risk of venous thromboembolism (VTE) is one of them. In this review, we …

[HTML][HTML] The structural biology of oestrogen metabolism

MP Thomas, BVL Potter - The Journal of steroid biochemistry and …, 2013 - Elsevier
Many enzymes catalyse reactions that have an oestrogen as a substrate and/or a product.
The reactions catalysed include aromatisation, oxidation, reduction, sulfonation …

[HTML][HTML] Endocrine and metabolic effects of an oral contraceptive containing estetrol and drospirenone

C Klipping, I Duijkers, M Mawet, C Maillard, A Bastidas… - Contraception, 2021 - Elsevier
Objectives To evaluate the effect on endocrine and metabolic parameters of a new
combined oral contraceptive (COC) containing estetrol (E4) and drospirenone (DRSP) …

Estetrol‐Drospirenone combination oral contraceptive: a clinical study of contraceptive efficacy, bleeding pattern and safety in Europe and Russia

K Gemzell‐Danielsson, D Apter, J Zatik… - … Journal of Obstetrics …, 2022 - Wiley Online Library
Objectives To assess the contraceptive efficacy, bleeding pattern and safety of a combined
oral contraceptive containing estetrol (E4) 15 mg and drospirenone (DRSP) 3 mg. Design …

Cardiovascular disease in transsexual persons treated with cross-sex hormones: reversal of the traditional sex difference in cardiovascular disease pattern

LJ Gooren, K Wierckx, EJ Giltay - European journal of …, 2014 - academic.oup.com
Objective The incidence of heart disease increases with age, but is lower in women than in
men up to 75 years. A protective effect of female sex hormones or, alternatively, acceleration …

Reduced hemostatic effects with drospirenone-based oral contraceptives containing estetrol vs. ethinyl estradiol

C Kluft, Y Zimmerman, M Mawet, C Klipping… - Contraception, 2017 - Elsevier
Objective The effects of estetrol (E4), a natural fetal estrogen, combined with drospirenone
(DRSP) were evaluated on plasma levels of sex hormone-binding globulin (SHBG) …

A novel estetrol-containing combined oral contraceptive: European expert panel review

K Gemzell-Danielsson, A Cagnacci… - … European Journal of …, 2022 - Taylor & Francis
Purpose Despite considerable advances in recently developed combined oral
contraceptives (COCs), resulting in lower rates of adverse events while maintaining …

[HTML][HTML] Choosing a combined oral contraceptive pill

M Stewart, K Black - Australian prescriber, 2015 - ncbi.nlm.nih.gov
The combined oral contraceptive pill is an effective contraceptive method which can also
offer other benefits. However, other contraceptive options should be discussed. If the pill is …

Hormonal replacement therapy in adolescents and young women with chemo-or radio-induced premature ovarian insufficiency: practical recommendations

A Cattoni, F Parissone, I Porcari, S Molinari, N Masera… - Blood Reviews, 2021 - Elsevier
In women with premature ovarian insufficiency (POI), hormonal therapy (HT) is indicated to
decrease the risk of morbidity and to treat symptoms related to prolonged hypoestrogenism …

[HTML][HTML] Pooled analysis of two phase 3 trials evaluating the effects of a novel combined oral contraceptive containing estetrol/drospirenone on bleeding patterns in …

AM Kaunitz, SL Achilles, J Zatik, S Weyers, T Piltonen… - Contraception, 2022 - Elsevier
Objective To evaluate the bleeding patterns of a new combined oral contraceptive
containing estetrol (E4) 15 mg/drospirenone (DRSP) 3 mg in a 24/4-day regimen. Study …